FutureChem Obtains Patent Related to Prostate Cancer Diagnosis

[Asia Economy Reporter Minwoo Lee] FutureChem announced on the 1st that it has obtained a patent for '18F-labeled compounds for prostate cancer diagnosis and their uses.' The company stated, "Compared to existing diagnostic methods, higher patient convenience and accurate diagnosis are expected," adding, "Currently, Phase 1 clinical trials are underway at the Korea Institute of Radiological & Medical Sciences, Seoul St. Mary's Hospital, and Johns Hopkins Hospital in the United States, and after filing patents in 16 countries worldwide, including Australia, the registration review is in progress."